IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection

Experts discuss their approaches to first-line renal cell carcinoma treatment selection, comparing immunotherapy (IO)-IO vs IO-tyrosine kinase inhibitor strategies.

EP: 1.CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC

EP: 2.Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC

EP: 3.From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum

EP: 4.From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses

EP: 5.Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC

EP: 6.Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management

Now Viewing

EP: 7.IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection

EP: 8.KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025

Recent Videos